Precision Medicine In Cell And Gene Therapy: Building Integrated Clinical Strategies For Complex Modalities

By Kim Watanabe, Ph.D., Amy Lavelle, Ph.D., director, laboratory operations, and Elizabeth Donahue, senior director, operations, observational studies

Cell and gene therapies are redefining precision medicine, but their clinical development introduces significant operational, regulatory, and scientific complexity. This article explores the unique challenges associated with advancing complex modalities, including restrictive patient eligibility, small study populations, long-term follow-up requirements, decentralized care models, and evolving global regulations. It highlights how integrated clinical strategies, digital monitoring tools, biomarker-driven decision-making, and patient-centric trial designs can help sponsors improve execution, evidence generation, and long-term outcomes. Readers will gain insight into how the industry is building scalable infrastructure and adaptive development models to support the future of complex cell and gene therapy programs.